Failure of repeated injection sclerotherapy to improve long-term survival after oesophageal variceal bleeding. A five-year prospective controlled clinical trial

Lancet. 1983 Dec 10;2(8363):1328-32. doi: 10.1016/s0140-6736(83)91090-5.

Abstract

The role of sclerotherapy in long-term management after oesophageal variceal bleeding was assessed by comparing repeated sclerotherapy by means of a rigid oesophagoscope in 37 patients with control medical management in 38 patients. Varices were eradicated in 21 of the 22 patients analysed (95%) in the sclerotherapy group, but recurred in 13 of the 21 patients (average 21.5 months). Varices persisted in 13 of 14 surviving controls. The sclerotherapy patients had fewer recurrent bleeds than control patients (43 versus 73); the majority occurred before variceal eradication and were mild. However, there was no difference in survival in the two groups. The commonest cause of death was liver failure (37 patients). 32 complications occurred in 24 patients during 258 injections. Repeated sclerotherapy failed to improve survival in this trial, although varices were eradicated and recurrent variceal bleeds were prevented with adequate follow-up.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Disease
  • Adolescent
  • Adult
  • Aged
  • Clinical Trials as Topic
  • Esophageal and Gastric Varices / mortality*
  • Esophageal and Gastric Varices / therapy
  • Esophagoscopes
  • Evaluation Studies as Topic
  • Female
  • Fiber Optic Technology
  • Gastrointestinal Hemorrhage / mortality
  • Gastrointestinal Hemorrhage / therapy
  • Humans
  • Male
  • Middle Aged
  • Prospective Studies
  • Random Allocation
  • Recurrence
  • Sclerosing Solutions / therapeutic use*
  • Time Factors

Substances

  • Sclerosing Solutions